This proposal is for a 5 year renewal (years 16-20) of the Alzheimer's Disease Cooperative Study (ADCS). This consortium of 34 members'sites and 46-56 participating sites is proposing both continued instrument development as well as new clinical drug studies. Instrument development will focus on innovative methods of home based assessments for a broad cohort of normal elderly(over age 75) who may have significant co-morbidities in a simulated primary prevention trial employing mail-in questionnaires, automated telephone technology and computerized data collection to assess cognitive, functional, affective, global, quality of life, and resource use measures in the home environment. The ADCS has assembled its most exciting portfolio of clinical drug trials by seeking new and innovative compounds form the biotechnology sector, individual investigator laboratories as well as from its own members. We are proposing 3 phase 3 efficacy trials of agents designed to slow progression of AD: (1) TTP488, a small novel molecule that binds to and inhibits the receptor for advanced glycation end products (RAGE) which blocks deposition of A?, (2) NAP, a novel eight amino acid peptide derived from the sequence of activity dependent neuroprotective protein(ADNP), the most potent neuroprotectant molecule currently known and (3) docosahexaenoic acid (DHA), an omega-3 fatty acid with anti-amyloid, anti-oxidant, and neuroprotectant effects. Two biomarker trials are proposed to determine if molecules of interest can produce a measurable biological signal for consideration for future efficacy trials: (1) Li, a molecule that blocks phosphorylation of tau protein and (2) resveratrol, a polyphenol derived from plants and red wine that retards the age-dependent deposition and accumulation of CNS A? and amyloid plaques. Finally, we will test the ability of passive immunization using Mg which contains natural anti-amyloid antibodies and has been demonstrated to improve cognition in early clinical trials in AD. Our existing minority recruitment core is being expanded into a general recruitment core focused on maximizing the recruitment of minorities and other subjects into our clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AG010483-21
Application #
8111766
Study Section
Special Emphasis Panel (ZAG1-ZIJ-7 (M2))
Program Officer
Ryan, Laurie M
Project Start
1997-07-01
Project End
2012-11-30
Budget Start
2011-07-01
Budget End
2012-11-30
Support Year
21
Fiscal Year
2011
Total Cost
$5,798,687
Indirect Cost
Name
University of California San Diego
Department
Neurosciences
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Tarrant, Sarah D; Bardach, Shoshana H; Bates, Kendra et al. (2016) The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's Disease. Alzheimer Dis Assoc Disord :
Yassine, Hussein N; Rawat, Varun; Mack, Wendy J et al. (2016) The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Alzheimers Res Ther 8:25
Ebbert, Mark T W; Boehme, Kevin L; Wadsworth, Mark E et al. (2016) Interaction between variants in CLU and MS4A4E modulates Alzheimer's disease risk. Alzheimers Dement 12:121-9
Ott, B R; Pelosi, M A; Tremont, G et al. (2016) A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure. Alzheimers Dement (N Y) 2:23-29
Jun, G; Ibrahim-Verbaas, C A; Vronskaya, M et al. (2016) A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry 21:108-17
Kennedy, Richard E; Cutter, Gary R; Wang, Guoqiao et al. (2016) Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical Trials. J Alzheimers Dis 50:1205-15
Risacher, Shannon L; McDonald, Brenna C; Tallman, Eileen F et al. (2016) Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurol 73:721-32
Zlatar, Zvinka Z; Bischoff-Grethe, Amanda; Hays, Chelsea C et al. (2016) Higher Brain Perfusion May Not Support Memory Functions in Cognitively Normal Carriers of the ApoE ε4 Allele Compared to Non-Carriers. Front Aging Neurosci 8:151
Reiman, Eric M; Langbaum, Jessica B; Tariot, Pierre N et al. (2016) CAP--advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol 12:56-61
Hohman, Timothy J; Cooke-Bailey, Jessica N; Reitz, Christiane et al. (2016) Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk. Alzheimers Dement 12:233-43

Showing the most recent 10 out of 270 publications